Abvc biopharma completes site initiation visits and begins enrollments for adhd phase ii part 2 clinical study

Fremont, ca, april 28, 2022 (globe newswire) -- via newmediawire - abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that all five clinical study sites in taiwan participating in the phase ii, part 2 clinical study of the company's adhd medicine have completed their site initiation visits (siv).
ABVC Ratings Summary
ABVC Quant Ranking